The inherited myopathies and muscular dystrophies are a diverse group of muscle diseases presenting with common complaints and physical signs: weakness, motor delay, and respiratory and bulbar dysfunction. The myopathies are caused by genetic defects in the contractile apparatus of muscle, and defined by distinctive histochemical or ultrastructural changes on muscle biopsy. The muscular dystrophies, in contrast, are diseases of muscle membrane or supporting proteins, which are generally characterized by pathological evidence of ongoing muscle degeneration and regeneration. Diagnosis of these disorders is contingent on a targeted history and examination, biochemical and neurophysiological assessment, muscle biopsy, and genetic testing. Treatment is focused on symptomatic management and rehabilitation, and monitoring for disease complications.
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The inherited myopathies and muscular dystrophies are a diverse group of muscle diseases presenting with common complaints and physical signs. The myopathies are caused by genetic defects in the contractile apparatus of muscle, and are defined by distinctive static histochemical or ultrastructural changes on muscle biopsy. 1 In contrast, the muscular dystrophies are diseases of muscle membrane or supporting proteins characterized by pathological evidence of ongoing muscle degeneration and regeneration. Diagnosis of these disorders is contingent on a targeted history and examination, biochemical and neurophysiological assessment, muscle biopsy, and genetic testing. This review provides a practical approach to the evaluation and investigation of inherited myopathies and muscular dystrophies. Data regarding the frequency of many of these disorders are surprisingly limited (Table 1) . 2 
CLINICAL FEATURES
The Congenital Myopathies The congenital myopathies were broadly grouped as amyotonia congenita before the first description of a discrete myopathy-central core disease-in 1956. 13 Dubowitz subsequently delineated several distinct myopathies (Table 2). 14 Congenital myopathies present in childhood with hypotonia, feeding and respiratory difficulties, and delayed motor milestones. Milder cases may present later in life with complications such as contractures, scoliosis, and respiratory insufficiency. There is wide variation in severity. Typical examination findings include proximal or generalized weakness, hypotonia and hyporeflexia, poor muscle bulk, and dysmorphic features secondary to muscle weakness (pectus carinatum, scoliosis, a high arched palate, and elongated facies). Weakness is usually static or slowly progressive. The respiratory muscles are usually involved, but cardiac involvement is rare. [15] [16] [17] The serum creatine kinase is normal or mildly elevated. Nerve conduction studies are normal. Electromyography may be normal or may show low-amplitude, polyphasic (myopathic) potentials. Myotonic discharges are occasionally seen in myotubular myopathy and the metabolic myopathies. Muscle biopsy shows changes specific to the myopathy, without necrotic or fibrotic changes.
Distal Myopathies
The distal myopathies are a heterogeneous group of myopathies and dystrophies. Age of onset is variable but generally between 40 and 60 years. 18 A clinical and genetic classification is shown in Table 3 .
MUSCULAR DYSTROPHIES

Congenital Muscular Dystrophies
The congenital muscular dystrophies (CMDs) present in the first year with hypotonia and weakness, respiratory insufficiency, bulbar dysfunction, and arthrogryposis. Hypertrophy of the tongue and limb muscles, scoliosis, and contractures may develop with age. Weakness is static or slowly progressive. The CMDs are caused by genetic defects in proteins of the sarcolemmal membrane or its supporting structures. The proteins may also be expressed in the central nervous system, and many forms of CMD are associated with structural brain and eye anomalies (Table 4) . Most are inherited in an autosomal recessive fashion. 19 The creatine kinase (CK) is markedly elevated. Nerve conduction studies may show demyelinating neuropathy in merosin-deficient CMD. 20 Electromyography (EMG) is myopathic. Muscle biopsy shows typical dystrophic changes (degeneration and regeneration of muscle fibers, and proliferation of fatty and connective tissue). Immunocytochemistry enables analysis of merosin, a-dystroglycan, collagen VI, and other muscle proteins. 19, 21 Cerebral magnetic resonance imaging may show abnormalities of neuronal migration and white matter signal. Specific genetic testing may be available.
Dystrophinopathies
The Duchenne and Becker forms of muscular dystrophy (DMD and BMD) result from mutations of the dystrophin gene on the X chromosome. DMD is the most common form of muscular dystrophy. Almost all boys with DMD are symptomatic before the age of 5 years, with difficulty running, jumping, and climbing steps; a waddling gait; and lumbar lordosis. Proximal weakness causes boys to use their arms in rising from the floor (Gowers' sign). Independent ambulation is lost by 14 years, with subsequent deterioration in respiratory function and development of contractures and scoliosis. 22 Static cognitive impairment is common. 23 Approximately one third of affected boys develop cardiomyopathy by the age of 14 years, and virtually all do after 18 years. Congestive heart failure and arrhythmias are common in end-stage DMD. 24 Most young men with DMD die in their late teens or early twenties from respiratory insufficiency or cardiac failure.
BMD usually presents between 5 and 15 years with a similar but milder phenotype. Myalgia and cramps may be prominent, and early cardiomyopathy is common. The distinction between DMD and BMD is made on the basis of age of wheelchair confinement (< 13 years in DMD and > 16 years in BMD). Death from respiratory failure or cardiomyopathy in BMD generally occurs between ages 30 and 60 years, but some men have a milder course. 22, 25 Uncommon dystrophinopathy variants include X-linked dilated cardiomyopathy, 26 isolated quadriceps myopathy, 27 and muscle cramps with myoglobinuria. 28 DMD/BMD carrier females may be asymptomatic or may have mild muscle weakness with an increased CK, calf hypertrophy, myalgia, and cramps, and are at risk of dilated cardiomyopathy. 29 Dystrophinopathies are a relatively common cause of hyperCKemic myopathy in women and should be considered in all women with a CK greater than 1000 and dystrophic myopathology. Approximately 50% of DMD carrier females will have no family history of neuromuscular disease. 30 Dystrophin immunocytochemistry in carrier or manifesting females shows a mosaic pattern, with a combination of fibers either containing or lacking dystrophin. Quantitative genetic studies or sequencing may then be confirmatory.
Before the age of 5 years, CK levels are 10 to 200 times normal levels in boys with DMD and BMD, but decline with advancing age. The CK does not differentiate between the dystrophinopathies. Nerve conduction studies are normal. Electromyography shows myopathic changes. Muscle biopsy in DMD shows degeneration, regeneration, and variability of fiber size with replacement of muscle by fat and connective tissue. Milder changes are seen in BMD. Muscle immunocytochemical studies with antidystrophin antibodies shows complete absence of staining in DMD, with normal, reduced, or patchy sarcolemmal staining in BMD.
The dystrophin gene is the largest gene yet identified in humans. 31 Dystrophin stabilizes and anchors the dystrophin-associated protein complex to the sarcolemmal membrane. Techniques used in genetic testing include the polymerase chain reaction (PCR), Southern blotting, mutation scanning, and/or sequence analysis. 22 DNA extracted from blood or white cells can be used for diagnosis. Deletions in the dystrophin gene are detected in 65% of patients with DMD and 85% of patients with BMD. Partial gene duplications, insertions/deletions, point mutations, or splicing errors are seen in a minority of patients. Quantitative assays of dystrophin predict phenotype. Patients with DMD have less than 5% of the normal quantity of dystrophin. Patients with BMD have at least 20% normal dystrophin levels. 32 Most patients with BMD (85%) have dystrophin of abnormal molecular weight, often with reduced dystrophin quantity. A minority have normal-sized protein of reduced quantity.
The general principles of management are discussed later in this article. Pulmonary function studies, electrocardiography, and echocardiography should be performed annually after age 10 years. Corticosteroids (prednisone and deflazacort) are the only treatments proven to improve strength and prolong ambulation in patients with DMD. 33 Side effects of steroids include weight gain, hypertension, behavioral changes, growth retardation, and cataracts. 33 Optimal dosage and dosing regimes remain under investigation. 34 Practice parameters for steroid therapy in DMD are available. 35 Advanced DMD is often complicated by cardiac conduction defects, resting tachycardia, and cardiomyopathy. Progression of cardiomyopathy in the dystrophinopathies may be slowed by treatment with b blockers and angiotensin-converting enzyme inhibitors. 36 A variety of genetic and pharmacological therapies are being studied for this condition. 37 
MYOTONIC DYSTROPHY
Myotonic Dystrophy Type 1 Myotonic dystrophy, or dystrophia myotonica 1 (DM1), is the most common muscular dystrophy in adults. DM1 is a multisystem disorder transmitted by autosomal dominant inheritance. The classical form of DM1 presents in childhood, but a neonatal form also occurs. 9 The main features of DM1 are myotonia, weakness, frontal balding (in males), cataracts, cardiomyopathy with conduction defects, and endocrinopathies. The face is long and myopathic, and there is difficulty with releasing the grasp or opening the eyes after sustained closure. Weakness and wasting are primarily distal and become more prominent in adulthood. Associated endocrinopathies include hyperinsulinism, hypothyroidism, and testicular atrophy. Smooth muscle involvement causes impaired gastrointestinal motility. With advancing age there may be a decline in cognitive function. Infants with congenital myotonic dystrophy usually inherit DM1 from their affected mother and present in infancy with hypotonia, facial diplegia, feeding, and respiratory difficulties. 22 Mental retardation is almost invariable, but myotonia is absent in neonates and infants. Cardiac arrhythmias may develop in adolescence and are often precipitated by physical exercise. 38 The CK is normal or mildly elevated in DM1. EMG shows myopathic potentials and myotonic discharges. Muscle histology is nonspecific, revealing internal nuclei and type I fiber atrophy without prominent dystrophic changes. Myotonic dystrophy type 1 is caused by expansion of a trinucleotide (CTG) repeat sequence in the myotonin-protein kinase (DMK) on chromosome 19 . 39 This repeat is stable in normal individuals, whose alleles contain < 50 copies. Mildly affected individuals or asymptomatic carriers have 50 to 80 CTG repeats. Persons with DM1 have more than 80 copies. There is a tendency for the CTG copy number to increase in successive generations of affected kindreds, causing earlier and more severe symptoms, a phenomenon known as genetic anticipation. The larger the repeat sequence in a mother, the greater likelihood her child will have congenital DM1. Genetic testing is virtually 100% accurate.
Treatment is symptomatic. Myotonia is usually mild and does not require treatment. Infants with congenital DM1 often require ventilatory support and gavage feeds. Patients with myotonic dystrophy require regular Holter monitoring and may require pacemaker placement. 40 Gastrointestinal dysfunction can be problematic. Delayed gastric emptying may respond to prokinetic agents (e.g., metoclopramide or cisapride). Diarrhea and cramping caused by bile acid malabsorption can improve with cholestyramine, but conservative treatment is usually required for symptoms of colonic dysmotility. 41 Myotonic Dystrophy Type 2 Myotonic dystrophy type 2 (DM2, also known as proximal myotonic myopathy, PROMM) is clinically similar but genetically distinct from DM1. 42 Distal, facial, and bulbar weakness is less prominent than in DM1, and there is no congenital form of DM2. The DM2 gene is on chromosome 3q13.3-q24, with expansion of a CCGT repeat in an intron of the zinc finger protein 9 gene.
Emery-Dreifuss Muscular Dystrophy
Emery-Dreifuss muscular dystrophy (EDMD) presents in late childhood or adult life 43 and is caused by mutations in the emerin (Xq28) or lamin A/C genes (1q21). 44, 45 Muscle weakness and wasting in EDMD has a humeroperoneal distribution, with weakness of the biceps and triceps and relative preservation of the deltoid muscles. Foot drop develops late. Contractures of the elbows and Achilles tendons are prominent, often early, manifestations of the disease. Cardiomyopathy and arrhythmias are common in adult life. Severe respiratory involvement is unusual in EDMD.
The CK is modestly elevated, with EMG and muscle biopsy showing nonspecific myopathic changes. Characteristic abnormalities on electrocardiography (ECG) include atrioventricular block and atrial arrhythmias. DNA testing is available for both the Xlinked and autosomal forms of EDMD, and has largely superseded muscle biopsy. 45, 46 Pacemaker installation may be lifesaving in patients with AV block.
Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly inherited dystrophy caused by a deletion within a sequence of 3.3 kb repeat units (called D4Z4) on chromosome 4. Normal individuals have at least 11 repeats of this sequence. Individuals with FSHD have 1 to 10 repeat units. 47 FSHD is variable in severity and age of onset. The classical form of FSHD presents in the second or third decade with facial weakness (inability to close the eyes tightly, smile, or whistle). There is atrophy of the biceps and triceps with relative preservation of the deltoid muscles. The scapulae are winged. Foot drop may develop. Progression is generally slow. Supraventricular arrhythmias occasionally complicate FSHD. The infantile form of FSHD presents in early childhood with severe, rapidly progressive generalized weakness. Infantile FSHD is often sporadic and may be associated with mental retardation, epilepsy, and sensorineural hearing loss. The CK is only mildly elevated, with EMG showing myopathic features. On muscle biopsy there is variability in fiber size and marked inflammatory changes. DNA testing is positive in 95 to 98% of typical cases.
Treatment includes regular ophthalmological review for exudative telangiectasia. Patients with severe arm weakness may benefit from surgical fixation of the scapulae. 48, 49 Immunosuppressive medications are ineffective despite the inflammatory response seen on muscle biopsies. Respiratory insufficiency occurs rarely, usually many years after disease onset.
Limb-Girdle Muscular Dystrophies
There are seven dominantly inherited (types 1A-G) and twelve recessively inherited (types 2A-K) forms of limbgirdle muscular dystrophies (LGMDs) ( Table 5) . 50 Mutations within the same gene may cause varying phenotypes. Most childhood-onset LGMDs are associated with lower extremity predominant weakness, with adult patients having increasing shoulder and pelvic girdle weakness, leading to restriction of mobility and eventually to wheelchair confinement. The neck flexors and extensors may be involved. Facial weakness is usually mild and, in some cases, totally absent. Cognition is usually normal. Cardiac or other systemic involvement is variable. 22 The CK is usually modestly elevated but can be very high in the sarcoglycanopathies, dysferlinopathy, and caveolinopathy. The autosomal recessive LGMDs generally have an earlier onset, more rapid progression and higher CK values than the dominant LGMDs. EMG shows myopathic changes and is particularly useful in discriminating mild forms of dominant LGMD, which may be associated with only very mild CK elevation, from spinal muscular atrophy type II and chronic inflammatory neuropathies. Muscle biopsy reveals typical dystrophic changes. Diagnosis is contingent on detailed histological and immunocytochemical testing of the muscle biopsy, which guides performance of Western blot and genetic testing for specific muscle proteins. Treatment is symptomatic. 22 Cardiac monitoring is re- LGMD, limb-girdle muscular dystrophy; EDMD, Emery-Dreifuss muscular dystrophy; AD, autosomal dominant; CK, creatine kinase.
quired in those LGMDs known to cause cardiomyopathy or arrhythmias (LGMD 1B, 1D, 2C-G, and 2I).
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Oculopharyngeal Muscular Dystrophy Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant myopathy generally seen in French-Canadians. 12 Oculopharyngeal muscular dystrophy is caused by a GCG repeat expansion in the PABP2 (poly-A binding protein 2) gene on chromosome 14q11, 51 and presents in middle age with ptosis, progressive ophthalmoplegia, dysarthria, and dysphagia, associated in some cases with limb weakness. CK levels may be elevated. Muscle biopsy shows fiber size variation and rimmed vacuoles. Treatment is symptomatic. Cricopharyngeal myotomy may improve dysphagia.
TREATMENT OF INHERITED MUSCLE DISORDERS
There are no curative treatments for the inherited myopathies or muscular dystrophies, but a multidisciplinary approach to the management of affected individuals can greatly improve quality of life and longevity. Disease-specific therapies were discussed previously. Treatment of individuals with these disorders should also address the considerations discussed in the following sections.
Symptomatic Therapy and Rehabilitation
The cornerstones of management are maintenance of strength and joint range of motion by exercise, physiotherapy, and avoidance of prolonged immobility. Passive stretching prevents contractures. Lightweight splints or orthotics may preserve independent ambulation for prolonged periods. Standing and/or walking may be maintained by the use of long-leg braces. Surgical release is indicated for contractures refractory to physiotherapy, if such surgery will result in improved function or will facilitate activities of daily living. 52 Progressive scoliosis can cause pain, loss of independent mobility, and difficulty in standing, sitting, or balancing. Respiratory function may be further compromised by the development of restrictive lung disease. Conservative treatment options include bracing and spinal fusion (arthrodesis). Bracing does not correct, prevent or reverse spinal curvature, but can improve sitting stability and is an alternative to surgery in nonambulatory patients. Operative stabilization generally halts the progression of spinal deformity, makes sitting more comfortable and helps preserve lung function, but is contraindicated if it is likely to impair motor function. The posterior surgical approach is considered the best way to prevent progression of spinal deformity. 52, 53 The most important factors related to the timing of surgery are residual flexibility of the spine and a pulmonary forced vital capacity more than 30% of the predicted value. 54 Monitoring: Developing a Plan for the Prospective Detection of Complications Most individuals with muscle diseases require physical and occupational therapy. Swallow assessments may also be required. All patients require regular monitoring for respiratory insufficiency. The extent of pulmonary compromise in neuromuscular disease depends on the pattern and severity of involvement of respiratory muscles, the development of secondary thoracic wall abnormalities, and resulting changes in lung compliance. 55 The initial manifestation of significant respiratory muscle weakness is excessive nocturnal apnea with desaturations, followed by development of hypercapnic alveolar hypoventilation and, ultimately, daytime respiratory failure. 56 Overnight intermittent positive pressure ventilation for chronic neuromuscular disorders treats symptomatic nocturnal hypoventilation, aids in recovery from respiratory infection, and reduces hospitalizations. 57 
RISK MANAGEMENT
Anesthesia Some inherited muscle diseases-particularly central core disease, dystrophinopathies, and multiminicore disease-are associated with malignant hyperthermia, a pharmacogenetic disorder characterized by an increase in skeletal muscle metabolism in response to certain inhalational agents (particularly halothane) and depolarizing muscle relaxants (particularly succinylcholine). 58 Patients with these disorders should only undergo surgery in centers with appropriate anesthetic expertise. Strength and range of motion can deteriorate rapidly after surgery and immobilization, and anesthesia can unmask subclinical respiratory failure. 59 Serial pulmonary function tests may guide timing of surgical intervention, and patients should be mobilized as soon as possible after surgery. 57 
Prevention
In the initial assessment of individuals with muscle disorders a detailed family history and examination of relatives is often informative. Subtle degrees of weakness may be identified in mildly affected relatives. In children, examination of the parents for myotonia is particularly important to exclude myotonic dystrophy. Definitive genetic counseling and prenatal diagnosis can generally only be offered when a disease-causing mutation has been identified.
Feeding Difficulties and Bulbar Dysfunction Neuromuscular disorders often cause feeding difficulties in infancy and can lead to aspiration, dysarthria, poor articulation, and poor control of secretions in older children. 15 Infants with feeding problems often require gavage feeds and/or insertion of a gastrostomy tube. Failure to thrive may relate both to poor intake and the increased metabolic demands imposed by chronic illness. 15 Drooling is often problematic but may respond to anticholinergic agents or salivary gland botulinum toxin injections. 60 
Cardiac Dysfunction
Symptomatic cardiomyopathy or cardiac arrhythmias is common in some muscular dystrophies, particularly CMD1C/LGMD 2I, LGMD 1A, and Emery-Dreifuss muscular dystrophy. Patients with these conditions should undergo annual cardiac review including ECG , echocardiography, and, where relevant, Holter monitoring. 61, 62 Cor pulmonale may also develop in muscle diseases associated with severe respiratory impairment.
FUTURE PROSPECTS
Additional genetic loci for the congenital myopathies and muscular dystrophies will continue to be identified. The development of new technologies for rapid automated detection of mutations (e.g., DNA microarrays) will greatly enhance our ability to provide accurate genetic counseling and prenatal diagnosis for patients with inherited muscle disorders. The identification of disease-causing mutations is the first step toward a better understanding of the pathogenesis of these disorders, and the development of ''curative'' rather than symptomatic therapies. Clinical trials are currently addressing the potential efficacy of gene therapy and myoblast transplantation in several muscular dystrophies. 63 
